Skip to main content

Table 1 Maternal characteristics of women with GDM treated vs. not treated with myoinositol

From: Myoinositol supplementation in the treatment of gestational diabetes mellitus: effects on glycaemic control and maternal-foetal outcomes

  Patients treated with myoinositol
N= 150
Patients not treated with myoinositol
N= 180
p
  Mean ± SD Mean ± SD  
 Age at GDM diagnosis (years) 32.6 ± 5.78 32.1 ± 5.48 0.412
 Pregestational BMI (Kg/m2) 28.8 ± 6.63 28.1 ± 6.37 0.266
 Pregestational weight (Kg) 75.3 ± 18.2 73.2 ± 18.7 0.281
 HbA1c at GDM diagnosis (%) 5.34 ± 0.48 5.35 ± 0.51 0.859
Oral glucose tolerance test at GDM diagnosis
 Fasting glycaemia (mmol/L) 95.7 ± 9.81 95.1 ± 10.9 0.770
 Glycaemia after 1 hour (mmol/L) 150.7 ± 36.5 163.5 ± 52.1 0.172
 Glycaemia after 2 hours (mmol/L) 115.8 ± 30.8 122.4 ± 37.6 0.364
 Gestational age at GDM diagnosis (weeks) 21.7 ± 4.92 23.6 ± 4.93 0.002
 Weight at delivery (Kg) 84.1 ± 17.2 81.7 ± 17.5 0.213
 Gestational age at delivery (weeks) 38.4 ± 1.18 38.7 ± 0.99 0.105
 Gestational age at start insulin therapy (weeks) 27.2 ± 5.13 27.7 ± 6.15 0.721
  Subjects (%) Subjects (%)  
Pregestational arterial hypertension 3 (2%) 9 (5%) 0.037
History of poliabortivity 35 (23.3%) 42 (23.3%) 0.601
Primipara 45 (30%) 68 (37.7%) 0.288
Multipara 105 (70%) 82 (45.5%)
BMI category
 Underweight (<18.5 kg/m2) 3 (2%) 3 (1.6%) 0.704
 Normal weight (18.5-24.9 kg/m2) 44 (29.3%) 54 (30%) 0.235
 Overweight (24.91-29.9 kg/m2) 52 (34.6%) 62 (34.4%) 0.412
 Obese (>29,9 kg/m2) 51 (34%) 61 (33.8%) 0.817
 Insulin treatment 52 (34.6%) 57 (31.6%) 0.723
• Long-acting insulin alone 31 (20.6%) 8 (4.4%) <0.001
• Short-acting insulin alone 10 (6.6%) 11 (6.1%) 0.989
• Basal-bolus insulin 11 (7.3%) 34 (18.8%) <0.001
Metformin treatment 5 (3.3%) 3 (1.6%) 0.744